Abstract 5370: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Research

• Publication date

  2011-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1538-7445.AM2011-5370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Breaking Resistance in BRAF-Mutant Melanoma: Novel Strategies and Biomarkers for Optimizing Targeted Therapies.

  2026cites this paper
• Unraveling BRAF alterations: molecular insights to circumvent therapeutic resistance across cancer types

  2025cites this paper
• Current and emerging treatment options for BRAFV600-mutant melanoma

  2025cites this paper
• Ferroptotic resistance involved in PTEN-loss prostate cancer progression

  2025cites this paper
• PTEN-mediated resistance in cancer: From foundation to future therapies

  2025cites this paper
• Defective biological networks associated with pseudogene-derived lncRNAs in cancer drug resistance: Promising prospects for their clinical targets in cancer therapy

  2025cites this paper
• Unravelling the Crosstalk: Anti-Fibrotic Agents and MAPK Inhibitors in the Treatment of Melanoma.

  2025cites this paper
• Molecular strategies in BRAF targeting: advances in patents, structure activity relationship and future prospects

  2025cites this paper
• Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review

  2025cites this paper
• Phosphatase and tensin homolog mRNA complexed with hyaluronated lipid nanoparticles for transdermal cancer immunotherapy.

  2025cites this paper
• Histopathological Subtypes of Cutaneous Melanoma: Prognostic and Molecular Implications

  2025cites this paper
• Radiogenomics of Stereotactic Radiotherapy: Genetic Mechanisms Underlying Radiosensitivity, Resistance, and Immune Response

  2025cites this paper
• Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?

  2025cites this paper
• Systemic treatment for a young patient with stage IV melanoma: A case report

  2025cites this paper
• Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma

  2024cites this paper
• Determinants of resistance and response to melanoma therapy

  2024cites this paper
• BRAF — a tumour-agnostic drug target with lineage-specific dependencies

  2024cites this paper
• A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers

  2024cites this paper
• Molecular Susceptibility and Treatment Challenges in Melanoma

  2024cites this paper
• Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches

  2024cites this paper
• Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers

  2024cites this paper
• Immune checkpoint inhibitors in metastatic melanoma therapy (Review)

  2024cites this paper
• Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition

  2024cites this paper
• Immunotherapy in melanoma: advances, pitfalls, and future perspectives

  2024cites this paper
• Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

  2023cites this paper
• Bcl-2 family inhibitors sensitize human cancer models to therapy

  2023cites this paper
• The GSTP1/MAPKs/BIM/SMAC modulatory actions of nitazoxanide: Bioinformatics and experimental evidence in subcutaneous solid Ehrlich carcinoma-inoculated mice.

  2023cites this paper
• Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions

  2023cites this paper
• Dual targeting of melanoma translation by MNK/eIF4E and PI3K/mTOR inhibitors.

  2023cites this paper
• UV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescents

  2023cites this paper
• Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution

  2023cites this paper
• Bioengineered MSC-derived exosomes in skin wound repair and regeneration

  2023cites this paper
• Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600‐mutant melanoma

  2023cites this paper
• MULTIPLATFORM ANALYSIS OF INTRATUMORAL PTEN HETEROGENEITY IN MELANOMA.

  2023cites this paper
• BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers

  2023influential citation
• Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China

  2022cites this paper
• CXCL10-coronated thermosensitive "stealth" liposomes for sequential chemoimmunotherapy in melanoma.

  2022cites this paper
• PTEN: a novel target for vitamin D in melanoma.

  2022cites this paper
• Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma

  2022cites this paper
• Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors

  2022cites this paper
• Cytoskeletal Remodelling as an Achilles’ Heel for Therapy Resistance in Melanoma

  2022cites this paper
• Cooperative induction of receptor tyrosine kinases contributes to adaptive MAPK drug resistance in melanoma through the PI3K pathway

  2022cites this paper
• Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer

  2022cites this paper
• Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors

  2022cites this paper
• The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways

  2022cites this paper
• Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance

  2022cites this paper
• Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer.

  2022cites this paper
• Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

  2022cites this paper
• Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives

  2022cites this paper
• Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo

  2021cites this paper
• Clinical cancer genomic profiling

  2021cites this paper
• Systemic Therapy of Metastatic Melanoma: On the Road to Cure

  2021cites this paper
• Advances in anti-BRAF therapies for lung cancer

  2021cites this paper
• Targeted mass-spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP kinase, and AKT signaling

  2021cites this paper
• The clinical benefit of molecular re-assessments in management of progressive lung cancer

  2021cites this paper
• PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN

  2021cites this paper
• Advances in the discovery and development of melanoma drug therapies

  2021influential citation
• Novel Biomarkers and Druggable Targets in Advanced Melanoma

  2021cites this paper
• Biomarkers in metastatic melanoma of the skin: can we more accurately choose the tactics of treating our patients?

  2021cites this paper
• Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in mediating targeted therapy dosage challenges

  2021cites this paper
• Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma

  2021cites this paper
• Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

  2021cites this paper
• Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma

  2021cites this paper
• CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma

  2021cites this paper
• Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

  2021cites this paper
• Re‐thinking therapeutic development for CNS metastatic disease

  2021cites this paper
• Signal pathways of melanoma and targeted therapy

  2021cites this paper
• PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

  2021cites this paper
• Implications thérapeutiques des mutations B-RAF dans le cancer colo-rectal

  2021cites this paper
• The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma

  2021cites this paper
• Mechanisms of Resistance to Targeted Therapies in Skin Cancers

  2021cites this paper
• Therapeutic implications of B-RAF mutations in colorectal cancer.

  2021cites this paper
• Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?

  2021cites this paper
• From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis

  2021influential citation
• Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response

  2021cites this paper
• The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma

  2021cites this paper
• Title: Deconvoluting mechanisms of acquired resistance to RAF inhibitors in BRAF V600E mutant human glioma

  2021cites this paper
• Role of RUNX2 in Melanoma: A New Player in Tumor Progression and Resistance to Therapy

  2021cites this paper
• Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy

  2020cites this paper
• Linhagens de células de melanoma: Mutações e impacto em vias de transdução de sinal / Melanoma cell lines: Mutations and impact on signal transduction pathways

  2020cites this paper
• The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma.

  2020cites this paper
• Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors

  2020cites this paper
• Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.

  2020cites this paper
• Oncogenic Tyrosine Phosphatases: Novel Therapeutic Targets for Melanoma Treatment

  2020cites this paper
• Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects

  2020cites this paper
• Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review

  2020cites this paper
• An amino-terminal BRAF deletion accounting for acquired resistance to RAF/EGFR inhibition in colorectal cancer

  2020cites this paper
• HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E

  2020cites this paper
• Targeted Therapy in Melanoma and Mechanisms of Resistance

  2020cites this paper
• MYBL2 regulates ATM to control replication initiation and prevent replication stress in pluripotent stem cells

  2020cites this paper
• CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma

  2020cites this paper
• The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma

  2020cites this paper
• Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

  2020cites this paper
• Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy

  2020cites this paper
• A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma

  2020cites this paper
• Nongenetic Mechanisms of Drug Resistance in Melanoma

  2020cites this paper
• Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes

  2020cites this paper
• Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma

  2020cites this paper
• Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?

  2020cites this paper
• Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?

  2020cites this paper